Cyclo Therapeutics Inc
NASDAQ:CYTH

Watchlist Manager
Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc
NASDAQ:CYTH
Watchlist
Price: 0.74 USD 4.23% Market Closed
Market Cap: 21.2m USD
Have any thoughts about
Cyclo Therapeutics Inc?
Write Note

Intrinsic Value

CYTH doesn't have a meaningful market cap.
CYTH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one CYTH stock under the Base Case scenario is 5.6 USD. Compared to the current market price of 0.74 USD, Cyclo Therapeutics Inc is Undervalued by 87%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

CYTH Intrinsic Value
5.6 USD
Undervaluation 87%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Cyclo Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for CYTH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about CYTH?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Cyclo Therapeutics Inc

Provide an overview of the primary business activities
of Cyclo Therapeutics Inc.

What unique competitive advantages
does Cyclo Therapeutics Inc hold over its rivals?

What risks and challenges
does Cyclo Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Cyclo Therapeutics Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Cyclo Therapeutics Inc.

Provide P/S
for Cyclo Therapeutics Inc.

Provide P/E
for Cyclo Therapeutics Inc.

Provide P/OCF
for Cyclo Therapeutics Inc.

Provide P/FCFE
for Cyclo Therapeutics Inc.

Provide P/B
for Cyclo Therapeutics Inc.

Provide EV/S
for Cyclo Therapeutics Inc.

Provide EV/GP
for Cyclo Therapeutics Inc.

Provide EV/EBITDA
for Cyclo Therapeutics Inc.

Provide EV/EBIT
for Cyclo Therapeutics Inc.

Provide EV/OCF
for Cyclo Therapeutics Inc.

Provide EV/FCFF
for Cyclo Therapeutics Inc.

Provide EV/IC
for Cyclo Therapeutics Inc.

Show me price targets
for Cyclo Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Cyclo Therapeutics Inc?

How accurate were the past Revenue estimates
for Cyclo Therapeutics Inc?

What are the Net Income projections
for Cyclo Therapeutics Inc?

How accurate were the past Net Income estimates
for Cyclo Therapeutics Inc?

What are the EPS projections
for Cyclo Therapeutics Inc?

How accurate were the past EPS estimates
for Cyclo Therapeutics Inc?

What are the EBIT projections
for Cyclo Therapeutics Inc?

How accurate were the past EBIT estimates
for Cyclo Therapeutics Inc?

Compare the revenue forecasts
for Cyclo Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Cyclo Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Cyclo Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Cyclo Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Cyclo Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Cyclo Therapeutics Inc with its peers.

Analyze the financial leverage
of Cyclo Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Cyclo Therapeutics Inc.

Provide ROE
for Cyclo Therapeutics Inc.

Provide ROA
for Cyclo Therapeutics Inc.

Provide ROIC
for Cyclo Therapeutics Inc.

Provide ROCE
for Cyclo Therapeutics Inc.

Provide Gross Margin
for Cyclo Therapeutics Inc.

Provide Operating Margin
for Cyclo Therapeutics Inc.

Provide Net Margin
for Cyclo Therapeutics Inc.

Provide FCF Margin
for Cyclo Therapeutics Inc.

Show all solvency ratios
for Cyclo Therapeutics Inc.

Provide D/E Ratio
for Cyclo Therapeutics Inc.

Provide D/A Ratio
for Cyclo Therapeutics Inc.

Provide Interest Coverage Ratio
for Cyclo Therapeutics Inc.

Provide Altman Z-Score Ratio
for Cyclo Therapeutics Inc.

Provide Quick Ratio
for Cyclo Therapeutics Inc.

Provide Current Ratio
for Cyclo Therapeutics Inc.

Provide Cash Ratio
for Cyclo Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Cyclo Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Cyclo Therapeutics Inc?

What is the current Free Cash Flow
of Cyclo Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Cyclo Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Cyclo Therapeutics Inc

Current Assets 4.5m
Cash & Short-Term Investments 1.1m
Receivables 83.7k
Other Current Assets 3.2m
Non-Current Assets 267.7k
PP&E 267.7k
Current Liabilities 9.8m
Accounts Payable 5.5m
Accrued Liabilities 1.6m
Short-Term Debt 2.7m
Non-Current Liabilities 12.4k
Other Non-Current Liabilities 12.4k
Efficiency

Earnings Waterfall
Cyclo Therapeutics Inc

Revenue
1.1m USD
Cost of Revenue
-95.6k USD
Gross Profit
1m USD
Operating Expenses
-22.2m USD
Operating Income
-21.2m USD
Other Expenses
416.9k USD
Net Income
-20.7m USD

Free Cash Flow Analysis
Cyclo Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

CYTH Profitability Score
Profitability Due Diligence

Cyclo Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional ROE
Exceptional ROIC
45/100
Profitability
Score

Cyclo Therapeutics Inc's profitability score is 45/100. The higher the profitability score, the more profitable the company is.

CYTH Solvency Score
Solvency Due Diligence

Cyclo Therapeutics Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Low D/E
Positive Net Debt
Long-Term Solvency
Short-Term Solvency
26/100
Solvency
Score

Cyclo Therapeutics Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

CYTH Price Targets Summary
Cyclo Therapeutics Inc

Wall Street analysts forecast CYTH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CYTH is 0.97 USD with a low forecast of 0.96 USD and a high forecast of 1 USD.

Lowest
Price Target
0.96 USD
30% Upside
Average
Price Target
0.97 USD
31% Upside
Highest
Price Target
1 USD
35% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for CYTH?

Click here to dive deeper.

Dividends

Cyclo Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for CYTH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

CYTH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Cyclo Therapeutics Inc Logo
Cyclo Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

21.2m USD

Dividend Yield

0%

Description

Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. The company is headquartered in Gainesville Florida, Florida and currently employs 9 full-time employees. The company went IPO on 2004-02-27. The firm's lead drug candidate, Trappsol Cyclo (hydroxypropyl beta cyclodextrin) is for the treatment of Niemann-Pick Type C disease (NPC). NPC is a rare and fatal cholesterol metabolism disease that impacts the brain, lungs, liver, spleen, and other organs. The company is also focusing on the use of cyclodextrins in the treatment of Alzheimer's disease. The firm's product lines include Trappsol and Aquaplex. The company sells its chemical products directly to customers in the pharmaceutical, diagnostics, and industrial chemical industries, and to chemical supply distributors. The firm also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

Contact

FLORIDA
Gainesville Florida
6714 Nw 16Th Street,, Suite B
+13864188060.0
www.cyclotherapeutics.com

IPO

2004-02-27

Employees

9

Officers

CEO & Director
Mr. N. Scott Fine
Founder & Director
Mr. C. E Strattan
CFO & Secretary
Mr. Joshua M. Fine
Senior VP of Business Development & Chief Regulatory Officer
Mr. Michael Eric Lisjak
COO, Chief Quality Officer & Director
Dr. Jeffrey L. Tate Ph.D.
Global Head of Patient Advocacy
Ms. Lori McKenna
Show More
Interim Chief Medical Officer
Dr. Karen Mullen FFPM
Show Less

See Also

Discover More
What is the Intrinsic Value of one CYTH stock?

The intrinsic value of one CYTH stock under the Base Case scenario is 5.6 USD.

Is CYTH stock undervalued or overvalued?

Compared to the current market price of 0.74 USD, Cyclo Therapeutics Inc is Undervalued by 87%.

Back to Top